|
Ovarian Carcinoma
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
CDK12 is a recurrently mutated gene in serous ovarian carcinoma, whose downregulation is associated with impaired expression of DNA damage repair genes and subsequent hypersensitivity to DNA-damaging agents and PARP1/2 inhibitors.
|
26787835 |
2016 |
|
Ovarian Carcinoma
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
CDK12 mutations have been reported in many cancers and have been suggested as a cause of defective DNA repair in ovarian carcinoma.
|
27662623 |
2016 |
|
Ovarian Carcinoma
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
CDK12 is among only nine genes with recurrent somatic mutations in high-grade serous ovarian carcinoma.
|
25712099 |
2015 |
|
Malignant neoplasm of prostate
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Moreover, CDK12-inactivating mutations together with the TD-plus phenotype were also observed in prostate cancers.
|
26787835 |
2016 |
|
Malignant neoplasm of prostate
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
The median follow-up was 66.6 mo.Patients with CDK12 mutant prostate cancer exhibited shorter time to metastasis (median = 34.9 mo, p = 0.004) and development of castration-resistant disease (median = 32.7 mo, p < 0.001), compared with other genomic subtypes, with shorter time to PSA progression on first-line ARPI treatment of metastatic castration-resistant disease (median = 3.6 mo, p = 0.0219).
|
31640893 |
2020 |
|
Malignant neoplasm of ovary
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
This genomic instability, denoted as the CDK12 TD-plus phenotype, is remarkably distinct from other alteration patterns described in breast and ovarian cancers.
|
26787835 |
2016 |
|
Malignant neoplasm of ovary
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
CDK12 is among only nine genes with recurrent somatic mutations in high-grade serous ovarian carcinoma.
|
25712099 |
2015 |
|
Malignant neoplasm of ovary
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
CDK12 mutations have been reported in many cancers and have been suggested as a cause of defective DNA repair in ovarian carcinoma.
|
27662623 |
2016 |
|
Adenocarcinoma of large intestine
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CDK12 is a kinase associated with elongating RNA polymerase II (RNAPII) and is frequently mutated in cancer.
|
31347271 |
2019 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We propose that CDK12 is a tumor suppressor of which the loss-of-function mutations may elicit defects in multiple DNA repair pathways, leading to genomic instability underlying the genesis of the cancer.
|
25712099 |
2015 |
|
Primary biliary cirrhosis
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis.
|
21399635 |
2011 |
|
Forced expiratory volume function
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets.
|
28166213 |
2017 |
|
Glomerular Filtration Rate
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Trans-ethnic kidney function association study reveals putative causal genes and effects on kidney-specific disease aetiologies.
|
30604766 |
2019 |
|
Glomerular Filtration Rate
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
1000 Genomes-based meta-analysis identifies 10 novel loci for kidney function.
|
28452372 |
2017 |
|
Glomerular Filtration Rate
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A catalog of genetic loci associated with kidney function from analyses of a million individuals.
|
31152163 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In this report, we evaluate the clinical characteristics and outcomes of patients with prostate cancer and CDK12 mutation in their tumors.
|
31640893 |
2020 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CDK12 mutant cases are associated with elevated neoantigen burden ensuing from fusion-induced chimeric open reading frames and increased tumor T cell infiltration/clonal expansion.
|
29906450 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This analysis identified both pervasive subclonal somatic point-mutations and a small subset of predominantly clonal and homozygous mutations, which were overrepresented in the tumor suppressor genes TP53 and NF1 and in a candidate tumor suppressor gene CDK12.
|
22544022 |
2012 |
|
Adenocarcinoma of lung (disorder)
|
0.100 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
|
Creatinine measurement, serum (procedure)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
1000 Genomes-based meta-analysis identifies 10 novel loci for kidney function.
|
28452372 |
2017 |
|
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We propose that CDK12 is a tumor suppressor of which the loss-of-function mutations may elicit defects in multiple DNA repair pathways, leading to genomic instability underlying the genesis of the cancer.
|
25712099 |
2015 |
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CDK12 is a kinase associated with elongating RNA polymerase II (RNAPII) and is frequently mutated in cancer.
|
31347271 |
2019 |